1
|
Slay RM, Hatch GJ, Hewitt JA. Evaluation of Amoxicillin and Amoxicillin-Clavulanate (Augmentin) for Antimicrobial Postexposure Prophylaxis Following Bacillus anthracis Inhalational Exposure in Cynomolgus Macaques. Clin Infect Dis 2022; 75:S402-S410. [PMID: 36251552 PMCID: PMC9649419 DOI: 10.1093/cid/ciac572] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
Abstract
Amoxicillin is a broad-spectrum antibiotic used to treat a variety of gram-positive and gram-negative infections, such as infections of the ear, nose, and throat, genitourinary tract, skin, and lower respiratory tract; gonorrhea; and Helicobacter pylori. The prophylactic benefit of both amoxicillin and Augmentin (amoxicillin-clavulanate for use against β-lactamase-expressing bacteria) was evaluated for inhalation anthrax in cynomolgus macaques in 2 studies. A pilot study on amoxicillin-clavulanate that used a portion of the study animals demonstrated empirically that dosing twice a day was efficacious. In a subsequent study on both amoxicillin and amoxicillin-clavulanate that used the remaining study animals, the animals were treated orally every 12 hours on days 1-28 postchallenge and followed for an additional 60 days (total of 88 days from day of aerosol challenge to when the animals were culled). The animals from each treatment arm of the 2 studies were completely protected. All untreated animals succumbed to the infection. The degree of protection observed in this study suggests that both amoxicillin and amoxicillin-clavulanate, administered prophylactically over a period of 28 days after a lethal exposure to Bacillus anthracis spores, is sufficient for full protection.
Collapse
Affiliation(s)
- Raymond M Slay
- Correspondence: R. M. Slay, National Institute of Allergy and Infectious Diseases, 5601 Fishers Lane, 8G57, Bethesda, MD 20892-9825, USA ()
| | - Graham J Hatch
- Centre for Emergency Preparedness and Response, Public Health England, Porton Down, Wilton, United Kingdom
| | - Judith A Hewitt
- National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
| |
Collapse
|
2
|
Slay RM, Hewitt JA, Crumrine M. Determination of the Postexposure Prophylactic Benefit of Oral Azithromycin and Clarithromycin Against Inhalation Anthrax in Cynomolgus Macaques. Clin Infect Dis 2022; 75:S411-S416. [PMID: 36251550 PMCID: PMC9989359 DOI: 10.1093/cid/ciac569] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
Abstract
BACKGROUND Sufficient and diverse medical countermeasures against severe pathogenic infections, such as inhalation anthrax, are a critical need. Azithromycin and clarithromycin are antimicrobials commonly used for both upper and lower respiratory infections. They inhibit protein synthesis by blocking the formation of the 50S ribosomal subunit. To expand the armamentarium, these 2 antibiotics were evaluated in a postexposure prophylactic model of inhalation anthrax in cynomolgus macaques. METHODS This prophylaxis study had 4 test arms: azithromycin, clarithromycin, a levofloxacin control, and a placebo. Beginning 24 hours after exposure to a target challenge dose of 200 lethal dose 50 (LD50) of Bacillus anthracis Ames spores, animals were treated orally until 30 days postchallenge and then observed until 75 days postchallenge. RESULTS The test group that received clarithromycin had a survival rate of 67%. The test group that received azithromycin had a survival rate of 50%, but the peak azithromycin plasma levels achieved were <30 ng/mL-much lower than the expected 410 ng/mL. The levofloxacin positive control had a survival rate of 50%; all of the negative controls succumbed to infection. CONCLUSIONS The efficacy of clarithromycin prophylaxis was statistically significant compared with placebo, while azithromycin prophylaxis was indistinguishable from placebo. Given the low plasma concentrations of azithromycin achieved in the study, it is not surprising that half the animals succumbed to anthrax during the dosing period; the animals that survived beyond the time during which placebo control animals succumbed survived to the end of the observation period.
Collapse
Affiliation(s)
- Raymond M Slay
- National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
| | - Judith A Hewitt
- National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
| | - Martin Crumrine
- National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
| |
Collapse
|
3
|
Hewitt JA, Lanning LL, Campbell JL. The African Green Monkey Model of Pneumonic Plague and US Food and Drug Administration Approval of Antimicrobials Under the Animal Rule. Clin Infect Dis 2021; 70:S51-S59. [PMID: 32435803 DOI: 10.1093/cid/ciz1233] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND Additional treatment options for pneumonic plague, the most severe form of infection by Yersinia pestis, are needed, as past US Food and Drug Administration (FDA) approvals were not based on clinical trials that meet today's standards, and multiple drugs are sought to counter resistance or use in special populations. Due to the sporadic nature of outbreaks and the low number of pneumonic cases of disease, we sought FDA approval of antimicrobials for treatment under the Animal Efficacy Rule, where efficacy can be demonstrated in 1 or more well-characterized animal models that sufficiently represent human disease. METHODS A model was developed in African green monkeys (AGMs) after challenge with a lethal dose of Y. pestis delivered as an aerosol, in 4 independent studies in 3 laboratories. The primary data points were bacteremia (daily), body temperature and heart rate (continuously monitored by telemetry), and survival. In antimicrobial efficacy studies, human-equivalent doses of gentamicin, ciprofloxacin, levofloxacin, and doxycycline were administered upon fever onset for 10 days. RESULTS Disease in AGMs was similar to case reports of human disease. Fever was determined to be a reliable sign of disease and selected as a treatment trigger. Gentamicin was 60%-80% effective depending on the dose given to animals. Ciprofloxacin and levofloxacin were found to be >90% efficacious. These data were submitted to FDA and plague indications were approved. Doxycycline was less effective. CONCLUSIONS The AGM model of pneumonic plague is reproducible, well-characterized, and mimics human disease. It has been used to support plague indications for fluoroquinolones and to test the efficacy of additional antimicrobials.
Collapse
Affiliation(s)
- Judith A Hewitt
- Office of Biodefense, Research Resources and Translational Research , Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, Rockville, Maryland, USA
| | - Lynda L Lanning
- Office of Regulatory Affairs, Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, Rockville, Maryland, USA
| | - Joseph L Campbell
- Office of Biodefense, Research Resources and Translational Research , Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, Rockville, Maryland, USA
| |
Collapse
|
4
|
Hewitt JA, Lutz C, Florence WC, Pitt MLM, Rao S, Rappaport J, Haigwood NL. ACTIVating Resources for the COVID-19 Pandemic: In Vivo Models for Vaccines and Therapeutics. Cell Host Microbe 2020; 28:646-659. [PMID: 33152279 PMCID: PMC7528903 DOI: 10.1016/j.chom.2020.09.016] [Citation(s) in RCA: 32] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
Abstract
The Preclinical Working Group of Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV), a public-private partnership spearheaded by the National Institutes of Health, has been charged with identifying, prioritizing, and communicating SARS-CoV-2 preclinical resources. Reviewing SARS-CoV-2 animal model data facilitates standardization and harmonization and informs knowledge gaps and prioritization of limited resources. To date, mouse, hamster, ferret, guinea pig, and non-human primates have been investigated. Several species are permissive for SARS-CoV-2 replication, often exhibiting mild disease with resolution, reflecting most human COVID-19 cases. More severe disease develops in a few models, some associated with advanced age, a risk factor for human disease. This review provides a snapshot that recommends the suitability of models for testing vaccines and therapeutics, which may evolve as our understanding of COVID-19 disease biology improves. COVID-19 is a complex disease, and individual models recapitulate certain aspects of disease; therefore, the coordination and assessment of animal models is imperative.
Collapse
Affiliation(s)
- Judith A Hewitt
- Office of Biodefense, Research Resources and Translational Research, Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
| | - Cathleen Lutz
- In Vivo Pharmacology, The Jackson Laboratory, Bar Harbor, ME 04609, USA
| | - William C Florence
- Office of Biodefense, Research Resources and Translational Research, Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
| | - M Louise M Pitt
- Office of the Commander, United States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA
| | - Srinivas Rao
- Sanofi Research and Development, Sanofi, Cambridge, MA 02139, USA
| | - Jay Rappaport
- Tulane National Primate Research Center, Tulane University, Covington, LA 70433, USA
| | - Nancy L Haigwood
- Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR 97006, USA.
| |
Collapse
|
5
|
Campbell JL, Fay MP, Lanning LL, Hewitt JA. Effect of Delaying Treatment on Efficacy of Ciprofloxacin and Levofloxacin in the African Green Monkey Model of Pneumonic Plague. Clin Infect Dis 2020; 70:S60-S65. [PMID: 32435805 PMCID: PMC7240338 DOI: 10.1093/cid/ciz1234] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND Ciprofloxacin and levofloxacin, 2 fluoroquinolone antimicrobials, are ≥90% effective for the treatment of inhalational plague when administered within 2-6 hours of fever onset in African green monkeys (AGM). Based on data in the AGM model, these antimicrobials were approved under the Food and Drug Administration's Animal Efficacy Rule. However, that data did not address the issue of how long treatment with these antimicrobials would remain effective after fever onset. METHODS The AGM model of pneumonic plague was used to explore the effect of delaying treatment with ciprofloxacin and levofloxacin on efficacy. In 2 studies, AGMs were challenged with inhaled lethal doses of Yersinia pestis. Treatment with ciprofloxacin and levofloxacin was initiated from 0 to up to 30 hours after fever onset. RESULTS Challenged animals all developed fever within 78 hours and were treated with ciprofloxacin (n = 27) or levofloxacin (n = 29) at various predetermined time points postfever. When administered 10 hours after fever onset, 10 days of ciprofloxacin and levofloxacin treatment remained very effective (90 or 100%, respectively). The efficacy of both antimicrobials declined as treatment initiation was further delayed. Statistical analyses estimated the treatment delay times at which half of the AGMs were no longer expected to survive as 19.7 hours for ciprofloxacin and 26.5 hours for levofloxacin. CONCLUSIONS This study demonstrates that there is a narrow window following fever onset during which ciprofloxacin and levofloxacin are fully effective treatment options for pneumonic plague in AGMs. Since the timing of disease is similar in humans and AGMs, these AGM data are reasonably likely to predict response times for treatment in humans.
Collapse
Affiliation(s)
- Joseph L Campbell
- Office of Biodefense, Research Resources and Translational Research, National Institute of Allergy and Infectious Diseases, Rockville, Maryland, USA
| | - Michael P Fay
- Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, Rockville, Maryland, USA
| | - Lynda L Lanning
- Office of Regulatory Affairs, National Institute of Allergy and Infectious Diseases, Rockville, Maryland, USA
| | - Judith A Hewitt
- Office of Biodefense, Research Resources and Translational Research, National Institute of Allergy and Infectious Diseases, Rockville, Maryland, USA
| |
Collapse
|
6
|
Williams MS, Baker MR, Guina T, Hewitt JA, Lanning L, Hill H, May JM, Fogtman B, Pittman PR. Retrospective Analysis of Pneumonic Tularemia in Operation Whitecoat Human Subjects: Disease Progression and Tetracycline Efficacy. Front Med (Lausanne) 2019; 6:229. [PMID: 31696118 PMCID: PMC6818494 DOI: 10.3389/fmed.2019.00229] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2019] [Accepted: 10/03/2019] [Indexed: 11/26/2022] Open
Abstract
Francisella tularensis is a highly infectious Gram-negative bacterium that is the etiologic agent of tularemia in animals and humans. The incidence of tularemia is very low with a lack of comprehensive data that describe disease in humans due to difficulty in understanding time and routes of exposure. Under the title Operation Whitecoat, researchers at Ft. Detrick, MD conducted 40 clinical studies of tularemia from 1958 to 1968. In these studies, one of the objectives was to evaluate candidate countermeasures for treatment or prophylaxis of disease after exposure to Francisella tularensis strain Schu S4 by inhalation. These studies were reviewed retrospectively to delineate the early signs and symptoms or natural history of pneumonic tularemia and examine the efficacy of tetracycline in controlled human clinical studies. Using vital signs, onset of fever was objectively defined and calculated for each subject, while Adverse Events reported after exposure were also used to define the timing of disease onset and symptoms of early disease. There was a dose response relationship between time to fever onset and exposed dose at 200 cfu (172.8 h), 700 cfu (163.2 h), 2,500 cfu (105.3 h), and 25,000 cfu (75.5 h). Onset of fever was typically the earliest sign of disease at all doses but was often accompanied by symptoms such as headache, myalgia, chest pain, and nausea, irrespective of dose except at 200 cfu where only 50% of subjects exhibited fever onset or symptoms. Examining the efficacy of different treatment regimens of tetracycline, ineffective treatments were indicated by relapse of disease (fever and Adverse Events) after cessation of antibiotic treatment. Stratification of the data suggested that treatment for <14 days or doses <2g/day was associated with increased percentage of subjects with relapse of disease symptoms. Although these types of human challenge studies would not be ethically possible now, the climate post-World War II supported human testing under rigorous conditions with informed consent. Thus, going back and analyzing these unique clinical human challenge studies has helped describe the course of infection and disease induced by a biothreat pathogen and possible countermeasures for treatment under controlled conditions.
Collapse
Affiliation(s)
- Mark S Williams
- Office of Biodefense Research Resources and Translational Research, Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States
| | - Marianne R Baker
- Office of Biodefense Research Resources and Translational Research, Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States
| | - Tina Guina
- Office of Biodefense Research Resources and Translational Research, Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States
| | - Judith A Hewitt
- Office of Biodefense Research Resources and Translational Research, Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States
| | - Lynda Lanning
- Office of Regulatory Affairs, Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States
| | | | | | - Beverly Fogtman
- Department of Clinical Research, United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD, United States
| | - Phillip R Pittman
- Department of Clinical Research, United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD, United States
| |
Collapse
|
7
|
DiCarlo AL, Cassatt DR, Dowling WE, Esker JL, Hewitt JA, Selivanova O, Williams MS, Price PW. Challenges and Benefits of Repurposing Products for Use during a Radiation Public Health Emergency: Lessons Learned from Biological Threats and other Disease Treatments. Radiat Res 2018; 190:659-676. [PMID: 30160600 DOI: 10.1667/rr15137.1] [Citation(s) in RCA: 25] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
The risk of a radiological or nuclear public health emergency is a major growing concern of the U.S. government. To address a potential incident and ensure that the government is prepared to respond to any subsequent civilian or military casualties, the U.S. Department of Health and Human Services and the Department of Defense have been charged with the development of medical countermeasures (MCMs) to treat the acute and delayed injuries that can result from radiation exposure. Because of the limited budgets in research and development and the high costs associated with bring promising approaches from the bench through advanced product development activities, and ultimately, to regulatory approval, the U.S. government places a priority on repurposing products for which there already exists relevant safety and other important information concerning their use in humans. Generating human data can be a costly and time-consuming process; therefore, the U.S. government has interest in drugs for which such relevant information has been established (e.g., products for another indication), and in determining if they could be repurposed for use as MCMs to treat radiation injuries as well as chemical and biological insults. To explore these possibilities, the National Institute of Allergy and Infectious Diseases (NIAID) convened a workshop including U.S. government, industry and academic subject matter experts, to discuss the challenges and benefits of repurposing products for a radiation indication. Topics covered included a discussion of U.S. government efforts (e.g. funding, stockpiling and making products available for study), as well unique regulatory and other challenges faced when repurposing patent protected or generic drugs. Other discussions involved lessons learned from industry on repurposing pre-license, pipeline products within drug development portfolios. This report reviews the information presented, as well as an overview of discussions from the meeting.
Collapse
Affiliation(s)
- Andrea L DiCarlo
- a Radiation and Nuclear Countermeasures Program (RNCP), Division of Allergy, Immunology and Transplantation (DAIT), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Rockville, Maryland
| | - David R Cassatt
- a Radiation and Nuclear Countermeasures Program (RNCP), Division of Allergy, Immunology and Transplantation (DAIT), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Rockville, Maryland
| | - William E Dowling
- b Office of Biodefense Research Resources and Translational Research (OBRRTR), Division of Microbiology and Infectious Diseases (DMID), NIAID, NIH, Rockville, Maryland
| | - John L Esker
- c Biomedical Advanced Research and Development Authority (BARDA), Office of the Assistant Secretary for Preparedness and Response (ASPR), Department of Health and Human Services (HHS), Washington, DC
| | - Judith A Hewitt
- b Office of Biodefense Research Resources and Translational Research (OBRRTR), Division of Microbiology and Infectious Diseases (DMID), NIAID, NIH, Rockville, Maryland
| | - Oxana Selivanova
- c Biomedical Advanced Research and Development Authority (BARDA), Office of the Assistant Secretary for Preparedness and Response (ASPR), Department of Health and Human Services (HHS), Washington, DC
| | - Mark S Williams
- b Office of Biodefense Research Resources and Translational Research (OBRRTR), Division of Microbiology and Infectious Diseases (DMID), NIAID, NIH, Rockville, Maryland
| | - Paul W Price
- d Office of Regulatory Affairs (ORA), DAIT, NIAID, NIH, Rockville, Maryland
| |
Collapse
|
8
|
Guina T, Lanning LL, Omland KS, Williams MS, Wolfraim LA, Heyse SP, Houchens CR, Sanz P, Hewitt JA. The Cynomolgus Macaque Natural History Model of Pneumonic Tularemia for Predicting Clinical Efficacy Under the Animal Rule. Front Cell Infect Microbiol 2018; 8:99. [PMID: 29670861 PMCID: PMC5893833 DOI: 10.3389/fcimb.2018.00099] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2017] [Accepted: 03/16/2018] [Indexed: 11/25/2022] Open
Abstract
Francisella tularensis is a highly infectious Gram-negative bacterium that is the etiologic agent of tularemia in animals and humans and a Tier 1 select agent. The natural incidence of pneumonic tularemia worldwide is very low; therefore, it is not feasible to conduct clinical efficacy testing of tularemia medical countermeasures (MCM) in human populations. Development and licensure of tularemia therapeutics and vaccines need to occur under the Food and Drug Administration's (FDA's) Animal Rule under which efficacy studies are conducted in well-characterized animal models that reflect the pathophysiology of human disease. The Tularemia Animal Model Qualification (AMQ) Working Group is seeking qualification of the cynomolgus macaque (Macaca fascicularis) model of pneumonic tularemia under Drug Development Tools Qualification Programs with the FDA based upon the results of studies described in this manuscript. Analysis of data on survival, average time to death, average time to fever onset, average interval between fever and death, and bacteremia; together with summaries of clinical signs, necropsy findings, and histopathology from the animals exposed to aerosolized F. tularensis Schu S4 in five natural history studies and one antibiotic efficacy study form the basis for the proposed cynomolgus macaque model. Results support the conclusion that signs of pneumonic tularemia in cynomolgus macaques exposed to 300–3,000 colony forming units (cfu) aerosolized F. tularensis Schu S4, under the conditions described herein, and human pneumonic tularemia cases are highly similar. Animal age, weight, and sex of animals challenged with 300–3,000 cfu Schu S4 did not impact fever onset in studies described herein. This study summarizes critical parameters and endpoints of a well-characterized cynomolgus macaque model of pneumonic tularemia and demonstrates this model is appropriate for qualification, and for testing efficacy of tularemia therapeutics under Animal Rule.
Collapse
Affiliation(s)
- Tina Guina
- National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States
| | - Lynda L Lanning
- National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States
| | | | - Mark S Williams
- National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States
| | - Larry A Wolfraim
- National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States
| | - Stephen P Heyse
- National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States
| | - Christopher R Houchens
- Biomedical Advanced Research and Development Authority, Department of Health and Human Services, Washington, DC, United States
| | - Patrick Sanz
- National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States
| | - Judith A Hewitt
- National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States
| |
Collapse
|
9
|
Hewitt JA, Brown LL, Murphy SJ, Grieder F, Silberberg SD. Accelerating Biomedical Discoveries through Rigor and Transparency. ILAR J 2017; 58:115-128. [PMID: 28575443 PMCID: PMC6279133 DOI: 10.1093/ilar/ilx011] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2016] [Revised: 03/07/2017] [Accepted: 03/16/2017] [Indexed: 12/13/2022] Open
Abstract
Difficulties in reproducing published research findings have garnered a lot of press in recent years. As a funder of biomedical research, the National Institutes of Health (NIH) has taken measures to address underlying causes of low reproducibility. Extensive deliberations resulted in a policy, released in 2015, to enhance reproducibility through rigor and transparency. We briefly explain what led to the policy, describe its elements, provide examples and resources for the biomedical research community, and discuss the potential impact of the policy on translatability with a focus on research using animal models. Importantly, while increased attention to rigor and transparency may lead to an increase in the number of laboratory animals used in the near term, it will lead to more efficient and productive use of such resources in the long run. The translational value of animal studies will be improved through more rigorous assessment of experimental variables and data, leading to better assessments of the translational potential of animal models, for the benefit of the research community and society.
Collapse
Affiliation(s)
- Judith A. Hewitt
- Judith A. Hewitt, PhD, is the Chief of the Research Resources Section in the Office of Biodefense, Research Resources and Translational Research, in the Division of Microbiology and Infectious Diseases at the National Institute of Allergy and Infectious Diseases in Bethesda, MD. Liliana L. Brown, PhD, is a Program Officer in the Office of Genomics and Advanced Technologies, in the Division of Microbiology and Infectious Diseases at the National Institute of Allergy and Infectious Diseases in Bethesda, MD. Stephanie J. Murphy, VMD, PhD, is the Director of the Division of Comparative Medicine within the Office of Infrastructure Programs in the Division of Program Coordination, Planning, and Strategic Initiatives in the Office of the Director at the National Institutes of Health in Bethesda, MD. Franziska Grieder, DVM, PhD, is the Director of the Office of Infrastructure Programs in the Division of Program Coordination, Planning, and Strategic Initiatives in the Office of the Director at the National Institutes of Health in Bethesda, MD. Shai D. Silberberg, PhD, is the Director of Research Quality at the National Institute of Neurological Disorders and Stroke in Bethesda MD.
| | - Liliana L. Brown
- Judith A. Hewitt, PhD, is the Chief of the Research Resources Section in the Office of Biodefense, Research Resources and Translational Research, in the Division of Microbiology and Infectious Diseases at the National Institute of Allergy and Infectious Diseases in Bethesda, MD. Liliana L. Brown, PhD, is a Program Officer in the Office of Genomics and Advanced Technologies, in the Division of Microbiology and Infectious Diseases at the National Institute of Allergy and Infectious Diseases in Bethesda, MD. Stephanie J. Murphy, VMD, PhD, is the Director of the Division of Comparative Medicine within the Office of Infrastructure Programs in the Division of Program Coordination, Planning, and Strategic Initiatives in the Office of the Director at the National Institutes of Health in Bethesda, MD. Franziska Grieder, DVM, PhD, is the Director of the Office of Infrastructure Programs in the Division of Program Coordination, Planning, and Strategic Initiatives in the Office of the Director at the National Institutes of Health in Bethesda, MD. Shai D. Silberberg, PhD, is the Director of Research Quality at the National Institute of Neurological Disorders and Stroke in Bethesda MD.
| | - Stephanie J. Murphy
- Judith A. Hewitt, PhD, is the Chief of the Research Resources Section in the Office of Biodefense, Research Resources and Translational Research, in the Division of Microbiology and Infectious Diseases at the National Institute of Allergy and Infectious Diseases in Bethesda, MD. Liliana L. Brown, PhD, is a Program Officer in the Office of Genomics and Advanced Technologies, in the Division of Microbiology and Infectious Diseases at the National Institute of Allergy and Infectious Diseases in Bethesda, MD. Stephanie J. Murphy, VMD, PhD, is the Director of the Division of Comparative Medicine within the Office of Infrastructure Programs in the Division of Program Coordination, Planning, and Strategic Initiatives in the Office of the Director at the National Institutes of Health in Bethesda, MD. Franziska Grieder, DVM, PhD, is the Director of the Office of Infrastructure Programs in the Division of Program Coordination, Planning, and Strategic Initiatives in the Office of the Director at the National Institutes of Health in Bethesda, MD. Shai D. Silberberg, PhD, is the Director of Research Quality at the National Institute of Neurological Disorders and Stroke in Bethesda MD.
| | - Franziska Grieder
- Judith A. Hewitt, PhD, is the Chief of the Research Resources Section in the Office of Biodefense, Research Resources and Translational Research, in the Division of Microbiology and Infectious Diseases at the National Institute of Allergy and Infectious Diseases in Bethesda, MD. Liliana L. Brown, PhD, is a Program Officer in the Office of Genomics and Advanced Technologies, in the Division of Microbiology and Infectious Diseases at the National Institute of Allergy and Infectious Diseases in Bethesda, MD. Stephanie J. Murphy, VMD, PhD, is the Director of the Division of Comparative Medicine within the Office of Infrastructure Programs in the Division of Program Coordination, Planning, and Strategic Initiatives in the Office of the Director at the National Institutes of Health in Bethesda, MD. Franziska Grieder, DVM, PhD, is the Director of the Office of Infrastructure Programs in the Division of Program Coordination, Planning, and Strategic Initiatives in the Office of the Director at the National Institutes of Health in Bethesda, MD. Shai D. Silberberg, PhD, is the Director of Research Quality at the National Institute of Neurological Disorders and Stroke in Bethesda MD.
| | - Shai D. Silberberg
- Judith A. Hewitt, PhD, is the Chief of the Research Resources Section in the Office of Biodefense, Research Resources and Translational Research, in the Division of Microbiology and Infectious Diseases at the National Institute of Allergy and Infectious Diseases in Bethesda, MD. Liliana L. Brown, PhD, is a Program Officer in the Office of Genomics and Advanced Technologies, in the Division of Microbiology and Infectious Diseases at the National Institute of Allergy and Infectious Diseases in Bethesda, MD. Stephanie J. Murphy, VMD, PhD, is the Director of the Division of Comparative Medicine within the Office of Infrastructure Programs in the Division of Program Coordination, Planning, and Strategic Initiatives in the Office of the Director at the National Institutes of Health in Bethesda, MD. Franziska Grieder, DVM, PhD, is the Director of the Office of Infrastructure Programs in the Division of Program Coordination, Planning, and Strategic Initiatives in the Office of the Director at the National Institutes of Health in Bethesda, MD. Shai D. Silberberg, PhD, is the Director of Research Quality at the National Institute of Neurological Disorders and Stroke in Bethesda MD.
| |
Collapse
|
10
|
|
11
|
|
12
|
Hewitt JA, De Souza DH. The Metabolism of Carbohydrates. Part II: On the possible occurrence of Stereochemical Changes in Equilibrated Solutions of Reducing Sugars introduced into the Circulation. Biochem J 2006; 15:667-71. [PMID: 16743039 PMCID: PMC1259032 DOI: 10.1042/bj0150667] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Affiliation(s)
- J A Hewitt
- The Department of Physiology, University of London, King's College
| | | |
Collapse
|
13
|
Pickering JW, Hewitt JA. Studies of the Coagulation of the Blood: Part I. Some Physico-Chemical Aspects of Coagulation. Biochem J 2006; 15:710-24. [PMID: 16743046 PMCID: PMC1259039 DOI: 10.1042/bj0150710] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Affiliation(s)
- J W Pickering
- The Physiology Department, University of London (King's College)
| | | |
Collapse
|
14
|
Hewitt JA, Pryde J. The Metabolism of Carbohydrates. Part I: Stereochemical Changes undergone by Equilibrated Solutions of Reducing Sugars in the Alimentary Canal and in the Peritoneal Cavity. Biochem J 2006; 14:395-405. [PMID: 16742944 PMCID: PMC1263893 DOI: 10.1042/bj0140395] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Affiliation(s)
- J A Hewitt
- The Physiology Laboratory, The University, St Andrews
| | | |
Collapse
|
15
|
Affiliation(s)
- J A Hewitt
- The Department of Physiology, University of London, King's College
| | | |
Collapse
|
16
|
Affiliation(s)
- J A Hewitt
- Department of Physiology, University of London (King's College)
| |
Collapse
|
17
|
Affiliation(s)
- J A Hewitt
- The Physiological Laboratory, St Andrews University
| |
Collapse
|
18
|
Affiliation(s)
- J W Pickering
- The Physiological Department, the University of London (King's College)
| | | |
Collapse
|
19
|
Fenton RA, Cottingham CA, Stewart GS, Howorth A, Hewitt JA, Smith CP. Structure and characterization of the mouse UT-A gene (Slc14a2). Am J Physiol Renal Physiol 2002; 282:F630-8. [PMID: 11880324 DOI: 10.1152/ajprenal.00264.2001] [Citation(s) in RCA: 63] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
The movement of urea across plasma membranes is modulated by facilitated urea transporter proteins. These proteins are the products of two closely related genes, termed UT-A (Slc14a2) and UT-B (Slc14a1). By genomic library screening and P1 artificial chromosome "shotgun" sequencing, we have determined the structure of the mouse UT-A gene. The gene is >300 kb in length, contains 24 exons, and has 2 distinct promoters. Flanking the 5'-region of the gene is the UT-Aalpha promoter that regulates transcription of UT-A1 and UT-A3. The second promoter, termed UT-Abeta, is present in intron 13 and regulates transcription of UT-A2. cAMP agonists (100 microM dibutryl cAMP, 25 microM forskolin, 0.5 mM IBMX) increased the activity of a 2.2-kb UT-Aalpha promoter construct 6.2-fold [from 0.026 +/- 0.003 to 0.160 +/- 0.004, relative light units (RLU)/microg protein] and a 2.4-kb UT-Abeta promoter construct 9.5-fold (from 0.020 +/- 0.002 to 0.190 +/- 0.043 RLU/microg protein) above that in untreated controls. Interestingly, only the UT-Abeta promoter contained consensus sequences for CREs and deletion of these elements abolished cAMP sensitivity. Increasing the tonicity of culture medium from 300 to 600 mosmol/kg H(2)O with NaCl caused a significant increase (from 0.060 +/- 0.004 to 0.095 +/- 0.010 RLU/microg protein) in UT-Aalpha promoter activity but had no effect on the UT-Abeta promoter. A tonicity-responsive enhancer was identified in UT-Aalpha and is suggested to be responsible for mediating this effect. Levels of UT-A2 and UT-A3 mRNA were increased in thirsted mice compared with control animals, indicating that the activities of both promoters are likely to be elevated during prolonged antidiuresis.
Collapse
Affiliation(s)
- R A Fenton
- School of Biological Sciences, University of Manchester, Manchester M13 9PT, United Kingdom
| | | | | | | | | | | |
Collapse
|
20
|
Abstract
Little is known about the embryonic factors that regulate the size of the primordial follicle endowment at birth. A few studies suggest that members of the B-cell lymphoma/leukemia-2 (bcl-2) family of protooncogenes may be important determinants. Thus, the purpose of this study was to test whether bcl-2 regulates the size of the primordial follicle pool at birth. To test this hypothesis, three lines of transgenic mice (c-kit/bcl-2 mice) were generated that overexpress human bcl-2 in an effort to reduce prenatal oocyte loss. The overexpression was targeted to the ovary and appropriate embryonic time period with the use of a 4.8-kilobase c-kit promoter. This promoter provided two to three times more expression of bcl-2 in the ovaries with minimal or no overexpression in most nongonadal tissues. On Postnatal Days 8-60, ovaries were collected from homozygous c-kit/bcl-2 and nontransgenic littermates (controls) and processed for histological evaluation of follicle numbers. All lines of c-kit/bcl-2 mice were born with significantly more primordial follicles than control mice (P < or = 0.05). By Postnatal Days 30-60, however, there were no significant differences in follicle numbers between c-kit/bcl-2 and control mice. These results indicate that bcl-2 overexpression increases the number of primordial follicles at birth, but that the surfeit of primordial follicles is not maintained in postnatal life. These data suggest that it is possible that the ovary may contain a census mechanism by which excess numbers of primordial follicles at birth are detected and removed from the ovary by adulthood.
Collapse
Affiliation(s)
- J A Flaws
- Departments of Epidemiology/Preventive Medicine, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA.
| | | | | | | | | |
Collapse
|
21
|
Abraham KM, Longo NS, Hewitt JA. Detection of transgene integrants and homologous recombinants in mice by polymerase chain reaction. Methods Mol Biol 1998; 92:245-50. [PMID: 9664520 DOI: 10.1385/0-89603-497-6:245] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Affiliation(s)
- K M Abraham
- Department of Microbiology and Immunology, University of Maryland, Baltimore, USA
| | | | | |
Collapse
|
22
|
Castelli JC, Hassel BA, Maran A, Paranjape J, Hewitt JA, Li XL, Hsu YT, Silverman RH, Youle RJ. The role of 2'-5' oligoadenylate-activated ribonuclease L in apoptosis. Cell Death Differ 1998; 5:313-20. [PMID: 10200477 DOI: 10.1038/sj.cdd.4400352] [Citation(s) in RCA: 139] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Abstract
Apoptosis of viral infected cells appears to be one defense strategy to limit viral infection. Interferon can also confer viral resistance by the induction of the 2-5A system comprised of 2'-5' oligoadenylate synthetase (OAS), and RNase L. Since rRNA is degraded upon activation of RNase L and during apoptosis and since both of these processes serve antiviral functions, we examined the role RNase L may play in cell death. Inhibition of RNase L activity, by transfection with a dominant negative mutant, blocked staurosporine-induced apoptosis of NIH3T3 cells and SV40-transformed BALB/c cells. In addition, K562 cell lines expressing inactive RNase L were more resistant to apoptosis induced by decreased glutathione levels. Hydrogen peroxide-induced death of NIH3T3 cells did not occur by apoptosis and was not dependent upon active RNAse L. Apoptosis regulatory proteins of the Bcl-2 family did not exhibit altered expression levels in the absence of RNase L activity. RNase L is required for certain pathways of cell death and may help mediate viral-induced apoptosis.
Collapse
Affiliation(s)
- J C Castelli
- Biochemistry Section, Surgical Neurology Branch, NINDS, NIH, Bethesda, Maryland 20892-1414, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Abstract
The 11p13 Wilms' tumor locus consists of two coordinately regulated transcripts, WT1 and WIT-1. These genes are highly expressed in the developing urogenital system, beginning with the urogenital ridge at day 10.5, the metanephric blastema at day 11.5, and during glomerular formation at day 13.5, becoming ultimately restricted to the podocytes. Stromal cells of the gonad also show abundant expression. WT1 is expressed at lower levels in spleen, uterus, mesothelial linings of organs in the abdominal and thoracic cavities, and the ependymal layer of the ventral aspect of the spinal cord. WIT-1 mRNA is about 10-fold less abundant than WT1, but appears to be expressed in the same tissue-restricted manner. Expression of the WT1 protein is required for kidney development, although its physiological function remains to be determined. The function of WIT-1 is similarly unknown but one intriguing possibility is that it is an antisense regulator of WT1. An understanding of events controlling spatial and temporal regulation of these genes will greatly improve our ability to study the role of WT1 and WIT-1 in urogenital development. We have found that while chimeric reporter constructs containing 0.6-2.5 kb of the 5' region of the WT1 gene direct transcription in many different cell lines, we were unable to detect expression in 13.5-day mouse embryos. However, a cosmid containing about 42 kb encompassing this region was able to direct the expression of abundant levels of mRNA from the appropriate transcription initiation sites in both stable transfectants of mouse Leydig cells (TM3) or in transgenic embryos. We are currently localizing the DNA elements required for this expression.
Collapse
Affiliation(s)
- J A Hewitt
- Department of Cancer Biology, Cleveland Clinic Foundation, Ohio 44195, USA
| | | | | | | |
Collapse
|
24
|
Campbell CE, Huang A, Gurney AL, Kessler PM, Hewitt JA, Williams BR. Antisense transcripts and protein binding motifs within the Wilms tumour (WT1) locus. Oncogene 1994; 9:583-95. [PMID: 8290269] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
Transcription of the WT1 locus is restricted, both temporally and spatially, to a subset of epithelial cells in mammalian kidneys and gonads. WT1, one of the two divergent transcripts mapping to this locus encodes a zinc finger protein that is likely a transcriptional regulator. The other transcript, WIT1, encodes a product of unknown function that is subject to alternate splicing in the region immediately 5' of the WT1 gene. Analysis of the 5' end of this locus further revealed the presence of multiple transcriptional start sites for both genes, such that some of the WIT1 transcripts are encoded by the antisense strand of the first exon of WT1. The genomic region surrounding the transcriptional start sites appears to constitute part of a bi-directional promoter based on the ability of a DNA fragment derived from this region to direct expression of a chimeric CAT gene construct in transient transfection assays. Discrete sequences within the region are capable of interaction in vitro with nuclear extracts derived from a variety of rat and mouse tissues. Interestingly, recombinant WT1, representing the product of zinc finger region of the most abundant of the four alternatively spliced transcripts, is also capable of binding to sequences within this region.
Collapse
Affiliation(s)
- C E Campbell
- Department of Cancer Biology, Cleveland Clinic Foundation, Ohio 44195
| | | | | | | | | | | |
Collapse
|
25
|
Affiliation(s)
- J A Hewitt
- Psychogeriatric Department, Barncoose Hospital, Redruth
| | | |
Collapse
|
26
|
Armstrong J, Hewitt JA, Perham RN. Chemical modification of the coat protein in bacteriophage fd and orientation of the virion during assembly and disassembly. EMBO J 1983; 2:1641-6. [PMID: 6357778 PMCID: PMC555339 DOI: 10.1002/j.1460-2075.1983.tb01638.x] [Citation(s) in RCA: 35] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022] Open
Abstract
The major (gene VIII) coat protein of bacteriophage fd was radiolabelled by treating the virus with methyl[3H]acetimidate without causing any loss of infectivity. Complete amidination of lysine-8 in the amino acid sequence of the protein was achieved but little or no modification of the lysine residues near the C terminus was observed. This supports the assumption that the coat protein is oriented in the viral filament with its N terminus on the outside and its C-terminal region abutting the DNA. Escherichia coli was co-infected with radiolabelled bacteriophage and with unlabelled miniphage, a shorter defective form of phage fd. Radiolabel was detected in the progeny miniphage, proving that individual coat protein subunits can be recycled and assembled onto progeny miniphage DNA. About 35% of the coat protein subunits of phage particles infecting E. coli were recycled in 1 h. These facts support a model of the assembly and disassembly of the virion at the bacterial membrane in which the end of the particle containing the minor adsorption (gene III) protein, which is presumably the first to disassemble during infection, is the last to assemble during morphogenesis.
Collapse
|
27
|
|
28
|
|
29
|
Hewitt JA, Allen G. Controlled proteolytic digestion of the M-protein of Sendai virus: the isolation of a fragment of 30000 molecular weight. J Gen Virol 1978; 39:311-9. [PMID: 206657 DOI: 10.1099/0022-1317-39-2-311] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
Proteolytic digestion of the M-protein of Sendai virus produces a product with a mol. wt. approximately 5000 less than that of the intact protein. In the case of digestion with chymotrypsin this cleavage is quite specific and the cleaved protein can be isolated. The smaller fragment appears to be physically removed from the larger (30000 mol. wt.) fragment, rather than remaining in non-covalent association with it. The cleavage is likely to be near the N-terminus of the protein. At the present time there is no indication of the biological function of this fragment.
Collapse
|
30
|
|
31
|
|
32
|
Abstract
A purification scheme is described for the M-protein of Sendai virus and an electron microscope study of the isolated protein is presented. The protein exists as subunits of 6 nm in diam., which possess a central hole; the subunits may be dimers of the polypeptide. They are able to form filamentous aggregates which wind around one another to form a helical structure. It is suggested that these filaments may be the form adopted by the protein in the virus, the filaments lying parallel to one another just beneath the virus membrane to form a shell, but that the helical form is likely to be a property only of the isolated protein.
Collapse
|
33
|
Kilmartin JV, Hewitt JA, Wootton JF. Alteration of functional properties associated with the change in quaternary structure in unliganded haemoglobin. J Mol Biol 1975; 93:203-18. [PMID: 1152051 DOI: 10.1016/0022-2836(75)90128-x] [Citation(s) in RCA: 93] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
|
34
|
Abstract
Satellite or defective bacteriophage particles can appear in extensively recycled stocks of coliphage M13. These particles, herein known as miniphage, replicate using the wild type bacteriophage as a helper. Their physical properties (u.v. spectra, sedimentation of DNA and bacterophage, electrophoretic moblitiy) are described and a method for the isolation of specific satellite bacteriophage is presented.
Collapse
|
35
|
|
36
|
Kilmartin JV, Hewitt JA. The effect of removal of C-terminal residues on cooperative interactions in hemoglobin. Cold Spring Harb Symp Quant Biol 1972; 36:311-4. [PMID: 4508144 DOI: 10.1101/sqb.1972.036.01.041] [Citation(s) in RCA: 44] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
|
37
|
Hewitt JA, Kilmartin JV, Eyck LF, Perutz MF. Noncooperativity of the dimer in the reaction of hemoglobin with oxygen (human-dissociation-equilibrium-sulfhydryl-absorption-x-ray analysis). Proc Natl Acad Sci U S A 1972; 69:203-7. [PMID: 4500548 PMCID: PMC427576 DOI: 10.1073/pnas.69.1.203] [Citation(s) in RCA: 46] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023] Open
Abstract
The theory that the alphabeta dimer is the functional unit of cooperativity in hemoglobin has been tested by determination of the oxygen equilibrium curve of stable deoxy dimers, obtained by the addition of 0.9 M MgCl(2) to human des-Arg 141alpha-hemoglobin. Cooperativity was absent in this medium, but was regained on transfer of the hemoglobin to a dilute phosphate buffer, where tetramers reformed. X-ray analysis of crystals of oxy- and deoxy-des-Arg hemoglobins showed that the removal of Arg 141alpha would leave the structure of alphabeta dimers unchanged. Nonreactivity of the sulfhydryl groups at 112beta proved that the subunits in deoxy dimers form the same contact as in oxy dimers, namely alpha(1)beta(1), and that no significant dissociation into free subunits occurs in 0.9 M MgCl(2). The absorption spectrum of the deoxy dimers corresponded to the sum of the spectra of the free deoxy alpha and beta subunits, and was different from that of the deoxy tetramer, showing the constraining salt bridges formed by the C-terminal residues in the tetramer to be necessary for the spectral changes normally observed on association of the deoxy subunits.
Collapse
|
38
|
Hewitt JA, Weiner M, Monzon OT, Rigler LG. The roentgen evaluation of bacteriuria associated with pregnancy. Radiology 1969; 93:104-8. [PMID: 4895544 DOI: 10.1148/93.1.104] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
|